TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratificat
Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupting microglia-specific regulatory elements, reflecting microglial dysfunction as a central AD pathogenic mechanism. Credible sets at loci with known effector genes (APOE, TREM2, PLCG2) will be smaller (<10 variants) due to stronger functional constraints, while novel loci will have larger sets requiring integration with epigenomic data to prioritize causal variants. The highest
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TREM2BiomarkerNeuroinflammation
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
TREM2 shows conflicting directions (negative, positive) across biomarker, neuroinflammation.
Verdict Summary
10/11
dimensions won
TREM2-Deficient Microglia as Drivers of
3/11
dimensions won
AD fine-mapping identifies causal varian
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.80
0.00
Evidence
0.88
0.72
Novelty
0.65
0.68
Feasibility
0.85
0.85
Impact
0.82
0.00
Druggability
0.90
0.00
Safety
0.72
0.00
Competition
0.68
0.00
Data
0.85
0.00
Reproducible
0.82
0.00
KG Connect
0.50
0.50
Score Breakdown
Dimension
TREM2-Deficient Microglia as D
AD fine-mapping identifies cau
Mechanistic
0.800
0.000
Evidence
0.880
0.720
Novelty
0.650
0.680
Feasibility
0.850
0.850
Impact
0.820
0.000
Druggability
0.900
0.000
Safety
0.720
0.000
Competition
0.680
0.000
Data
0.850
0.000
Reproducible
0.820
0.000
KG Connect
0.500
0.500
Evidence
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxic
No evidence citations yet
AD fine-mapping identifies causal variants in microglia-spec
No evidence citations yet
Debate Excerpts
TREM2-Deficient Microglia as Drivers of Amyloid Pl
4 rounds · quality: 0.81
Theorist
# Legacy Pre-Pipeline Hypotheses: Neurodegeneration
---
## Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
**Mechanism:** Misfolded α-synuclein (aSy...
Skeptic
# Critical Evaluation of Legacy Pre-Pipeline Hypotheses
## General Methodological Concerns (Cross-Cutting Issues)
Before evaluating individual hypotheses, several systemic weaknesses affect the enti...
Domain Expert
# Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses
## Preamble
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidenc...
Synthesizer
```json
{
"ranked_hypotheses": [
{
"title": "TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease",
"description": "TREM2 loss-of-function variants ...